Silence Therapeutics Plc (SLN)
$22.5
Insights on Silence Therapeutics Plc
Decreasing Revenue
Revenue is down for the last 4 quarters, 11.37M → 2.09M (in $), with an average decrease of 38.1% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, -8.25M → -14.41M (in $), with an average decrease of 74.7% per quarter
Performance
- $22.29$22.83$22.50
0.93%
Downside
Day's Volatility :2.37%
Upside
1.45%
- $4.55$27.72$22.50
79.78%
Downside
52 Weeks Volatility :83.59%
Upside
18.83%
Returns
| Period | Silence Therapeutics Plc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | 19.68% | -0.4% | 0.0% |
6 Months | 232.84% | 9.6% | 0.0% |
1 Year | 388.07% | 3.9% | -1.3% |
3 Years | -6.48% | 12.8% | -22.1% |
Highlights
Market Capitalization | 1.1B |
Book Value | $0.43 |
Earnings Per Share (EPS) | -1.45 |
Wall Street Target Price | 56.79 |
Profit Margin | -170.51% |
Operating Margin TTM | -633.59% |
Return On Assets TTM | -30.8% |
Return On Equity TTM | -221.19% |
Revenue TTM | 25.4M |
Revenue Per Share TTM | 0.68 |
Quarterly Revenue Growth YOY | -56.00000000000001% |
Gross Profit TTM | 6.6M |
EBITDA | -49.3M |
Diluted Eps TTM | -1.45 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | 0.0 |
EPS Estimate Next Year | 0.0 |
EPS Estimate Current Quarter | 0.0 |
EPS Estimate Next Quarter | 0.0 |
Analyst Recommendation
Analyst Forecast
What analysts predicted
Upside of 152.4%
Technicals Summary
Sell
Neutral
Buy
Silence Therapeutics Plc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Silence Therapeutics Plc | 2.93% | 232.84% | 388.07% | -6.48% | -6.48% |
 Moderna, Inc. | -5.36% | 32.83% | -24.38% | -39.84% | 322.91% |
 Regeneron Pharmaceuticals, Inc. | -6.34% | 13.15% | 12.94% | 84.22% | 161.57% |
 Novo Nordisk A/s | -2.94% | 28.97% | 46.95% | 238.27% | 414.84% |
 Vertex Pharmaceuticals Incorporated | -3.87% | 8.77% | 20.15% | 83.53% | 128.04% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Silence Therapeutics Plc | NA | NA | NA | 0.0 | -2.21 | -0.31 | NA | 0.43 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.22 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 25.77 | 25.77 | 1.46 | 45.22 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 46.13 | 46.13 | 2.4 | 3.33 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.39 | 28.39 | 0.53 | 16.72 | 0.23 | 0.13 | NA | 68.22 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Silence Therapeutics Plc | Buy | $1.1B | -6.48% | NA | -170.51% |
Moderna, Inc. | Buy | $38.8B | 322.91% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $98.4B | 161.57% | 25.77 | 30.14% |
Novo Nordisk A/s | Buy | $551.3B | 414.84% | 46.13 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $101.9B | 128.04% | 28.39 | 36.68% |
Institutional Holdings
Lombard Odier Asset Management USA Corp
10.03%Lombard Odier Asset Management (EU) Ltd
9.34%Artal Group S A
7.76%TCG Crossover Management, LLC
5.44%Deep Track Capital, LP
5.05%Bvf Inc
3.90%
Corporate Announcements
Silence Therapeutics Plc Earnings
Silence Therapeutics Plc’s price-to-earnings ratio stands at None
Read More
Company Information
silence therapeutics develops a new generation of medicines by harnessing the body’s natural mechanism of rna interference, or rnai, within its cells. our proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. using our enabling delivery systems, we have achieved an additional level of specificity by delivering our therapeutic rna molecules exclusively to target cells. silence’s proprietary rna chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases. for more information, visit us at www.silence-therapeutics.com
Organization | Silence Therapeutics Plc |
Employees | 109 |
CEO | Mr. Craig A. Tooman M.B.A. |
Industry | Health Technology |
